In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on 2seventy bio (TSVT – Research Report), with a price target of $28.00. The company’s shares opened today at $11.43.
Harrison covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and Editas Medicine. According to TipRanks, Harrison has an average return of 7.9% and a 53.46% success rate on recommended stocks.
Currently, the analyst consensus on 2seventy bio is a Strong Buy with an average price target of $29.33, a 156.61% upside from current levels. In a report released on January 20, Goldman Sachs also maintained a Buy rating on the stock with a $28.00 price target.
See today’s best-performing stocks on TipRanks >>
TSVT market cap is currently $418.6M and has a P/E ratio of -1.19.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TSVT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
2seventy bio Inc is primarely in the business of pharmaceutical preparations.
Read More on TSVT:
